海外の治験の状況「前立腺癌」での検索結果
242件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- Cabazitaxel in metastatic prostate cancer patients with AR-V7 positive CTCs
- metastatic castration-resistant prostate cancer;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
- Netherlands
- 2016-11-08
Authorised
- Study investigating intravenously administrated Oncocort in patients with metastatic prostate cancer
- Castration resistant prostate cancer with bone metastases. MedDRA version: 19.1 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Netherlands
- 2016-11-08
Authorised
- The BARCODE 2 Study – The Use of Genetic Profiling to Guide Prostate Cancer Treatment
- Prostate Cancer br>MedDRA version: 19.0 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- United Kingdom
- 2016-09-23
Authorised
- TOPARP: Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer
- Advanced Castration Resistant Prostate Cancer br>MedDRA version: 18.0 Level: LLT Classification code 10036910 Term: Prostate cancer NOS System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
- United Kingdom
- 2012-03-09
Authorised
- SAFETY, ABSORPTION AND DISTRIBUTION OF ODM-201 IN PATIENTS WITH PROSTATE CANCER:
- Progressive castration resistant prostate cancer (MedDRA: hormone-refractory prostate cancer) MedDRA version: 14.1 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Czech Republic, Finland, France, United Kingdom, United States
- 2010-11-15
Authorised
- SAFETY AND TOLERABILITY OF ODM-201 IN PATIENTS WITH PROSTATE CANCER: EXTENSION STUDY TO STUDY 3104001
- Progressive castration resistant prostate cancer (MedDRA: hormone-refractory prostate cancer) MedDRA version: 14.1 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Czech Republic, Finland, France, United Kingdom, United States
- 2010-11-15
Authorised
- Radium-223 & Enzalutamide metastatic prostate cancer study
- Metastatic castrate-resistant prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Ireland
- 2013-11-28
Authorised
- A multinational study to evaluate the safety and effectiveness of enzalutamide in patients whose prostate cancer has not metastasized
- Patients With Nonmetastatic Castration Resistant Prostate Cancer br>MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Denmark, Finland, France, Germany, Greece, Hong Kong, Italy, Korea, Republic of, Malaysia, Netherlands, New Zealand, Poland, Russian Federation, Serbia, Singapore, Slovakia, Spain, Sweden, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
- 2013-07-10
Authorised
- An international study of 177LU-PSMA-617 in the treatment of patients with progressive metastatic castration-resistant prostate cancer
- PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Belgium, Canada, Denmark, France, Germany, Netherlands, Sweden, United Kingdom, United States
- 2018-06-29
Authorised
- 68Ga-RM2 compared to 68Ga-PSMA-617 PET/CT for prostate cancer imaging according to various metastatic risks “UROPET”
- Prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]
- France
- 2018-02-27
